×
To start your customized experience click the start button
Customize ?  
Start
Cancer Types
Quick Links
Events
Award Programs
About Us
Careers
Contact Us
Newsroom
Privacy Policy
Terms & Conditions
 
Twitter
Face Book
YouTube
Instagram
 
 
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2019
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.

Lung Cancer

SPONSORED CONTENT BY MERCK IN COLLABORATION WITH GO2 FOUNDATION FOR LUNG CANCER
New Initiative Aims to Foster Informed Discussions Between Newly Diagnosed Lung Cancer Patients, Caregivers and Their Healthcare Team
 
Lung Cancer Foundation of America
Lung cancer survivors stage a takeover of Lung Cancer Foundation of America’s social media channels on World Lung Cancer Day August 1 to demonstrate what it means to be #livingwithlungcancer.
 
Katie Kosko
An expert sheds light on the importance of genomics in treating lung cancer.
Dr. Jorge Gomez
In an interview with CURE®, Dr. Jorge Gomez discussed how recent developments in the assessment of biomarkers within the small cell lung cancer and non-small cell lung cancer space have led to approvals of new and expanded therapies.
 
Ryan McDonald and Dr. Timothy Burns
Dr. Timothy Burns, of UPMC Hillman Cancer Center, discusses developments in the treatment of lung cancer over the next several years that have exciting potential to impact the field.
 
Ryan McDonald
The Food and Drug Administration in May approved 7 therapies to treat patients with non-small cell lung cancer. And although one expert notes that few are considered “practice changing”, patients should not be disheartened considering there have been so many advancements in the treatment of the disease.
 
Ryan McDonald
Most of the data from the recent approvals of several non-small cell lung cancer drugs don’t distinguish themselves regarding efficacy or safety to what was already available before the flurry of approvals in May, according to Dr. Timothy Burns.
 
Ryan McDonald and Timothy Burns
“One FDA approval that we were quite excited about (is Tabrecta). And I've actually already put some patients on it; it's a very good drug,” Dr. Timothy Burns said in a recent interview.
 
Ryan McDonald and Dr. Timothy Burns
The recent surge of drug approvals in the non-small cell lung cancer (NSCLC) space by the Food and Drug Administration (FDA) is quite unusual and only a fraction of them are considered practice changing, according to Dr. Timothy Burns.
 
Dr. Jorge Gomez
An expert explains the importance of the fourth approval of the immunotherapy Tecentriq for certain patients with metastatic non-small cell lung cancer who have a high PD-L1 expression.
 
×
×

Sign In

Not a member? Sign up now!
Continue without login
Continue
×